TL;DR
This review meticulously catalogs 57 newly identified natural compounds discovered between 2020 and April 2025 that inhibit PCSK9, a key protein regulating LDL cholesterol. By highlighting diverse plant-derived molecules and their mechanisms, this work provides a crucial update for researchers seeking novel, potentially safer, and more cost-effective alternatives to current hypercholesterolemia treatments.
What Problem Does This Paper Address?
High LDL cholesterol is a major risk factor for cardiovascular diseases. While statins and ezetimibe are common treatments, they can have side effects and high costs, driving the search for alternative therapies. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of LDL cholesterol levels, making it an attractive therapeutic target. Existing PCSK9 inhibitors, like monoclonal antibodies, are effective but can be expensive. This paper addresses the need for a comprehensive overview of naturally occurring PCSK9 inhibitors, focusing on recent discoveries to identify promising new leads from plants that could offer alternative therapeutic avenues.
Methods
This paper is a review article, not an experimental study. The authors systematically searched scientific literature (Web of Science, PubMed, Google Scholar, Scifinder) for publications from January 2020 to April 2025 that reported on natural products with PCSK9 inhibitory activity. They specifically excluded studies focusing solely on extracts or review articles, and also excluded previously reported findings on known PCSK9 inhibitors to focus on novel discoveries. The chemical structures of the identified compounds were drawn using ChemDraw software.
Datasets
Not discussed in the paper. This is a review of existing literature, not a study that generated new experimental data or datasets.
Key Insights and Ideas
- Nature's Pharmacy for Cholesterol Control: The sheer diversity of plant-derived compounds showing PCSK9 inhibitory activity underscores the vast, largely untapped potential of natural products for cardiovascular health.
- Beyond Monoclonal Antibodies: While antibody-based PCSK9 inhibitors are established, this review highlights that small molecules from plants can achieve similar effects, potentially offering different pharmacokinetic profiles, delivery methods, and cost structures.
- Mechanistic Diversity: The identified compounds don't all work the same way. They can suppress PCSK9 at the mRNA level, interfere with transcription factors (like HNF1α and SREBP2), enhance LDL receptor activity, or even inhibit PCSK9-LDLR binding, suggesting multiple points of intervention.
- Structural Variety is Key: The 57 compounds span a wide range of chemical classes – isoprenoids, flavonoids, alkaloids, and phenolic derivatives – indicating that different structural scaffolds can be effective PCSK9 inhibitors. This broadens the chemical space for drug discovery.
- Focus on Liver Action: Many compounds are evaluated in HepG2 (liver) cell lines, reflecting the liver's central role in PCSK9 production and cholesterol metabolism. Some studies even explore in vivo effects in animal models, bringing these natural compounds closer to clinical relevance.
Key Results
The review summarizes 57 newly identified compounds with PCSK9 inhibitory effects reported between January 2020 and April 2025. These compounds were isolated from 18 different plant species. They belong to various structural classes, including isoprenoids (1 diterpene, 3 sesquiterpenes, 15 triterpenes), triterpenoidal saponins, flavonoids, flavonoid glycosides, alkaloids, isocoumarins, lignans, nucleic acids, and stilbenes, among others. The identified compounds demonstrate various mechanisms of action, including suppression of PCSK9 mRNA expression, downregulation of transcription regulators (HNF1α, SREBP2, FOXO1, FOXO3), enhancement of LDLR activity, and inhibition of PCSK9-LDLR binding.
Limitations and Future Work
- In Vitro Dominance: A significant limitation noted is that most reported studies rely on in vitro experiments, primarily using HepG2 cell lines, with PCSK9 inhibition assessed at the mRNA level.
- Need for In Vivo Validation: To advance these compounds as viable therapeutic candidates, further in vivo investigations are crucial to confirm efficacy and safety in living organisms.
- Mechanistic Elucidation: While mechanisms are proposed, deeper understanding is needed. The authors suggest integrating RNA sequencing data with in silico approaches to identify precise interaction sites or direct protein targets.
- Clinical Translation: The ultimate goal is to develop drug candidates. This requires moving beyond cell-based assays to preclinical and clinical trials.
The authors emphasize that these efforts are expected to provide deeper insights into the underlying mechanisms of PCSK9 inhibition and pave the way for developing novel therapeutic agents.
Summary updated